СA-125 В РОЛИ НОВОГО БИОЛОГИЧЕСКОГО МАРКЕРА ПРИ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ (ОБЗОР ЛИТЕРАТУРЫ)

Аннотация

Сердечная недостаточность (СН) является одной из главных проблем современного здравоохранения. Исследования, сосредоточенные на поиске новых биологических маркеров, могут существенно повлиять на улучшение раннего выявления и выбор более эффективных методов терапии для пациентов с сердечно-сосудистыми заболеваниями. В спектр научных интересов исследователей в последнее время входит изучение углеводного антигена 125 (CA-125). CA-125 представляет собой высокомолекулярный трансмембранный гликопротеин, относящийся к семейству муцинов. Уровни CA-125 повышены почти у двух третей пациентов с острой СН. Клинические исследования, подчеркивают значимость СА-125 как биомаркера в контексте диагностики и прогноза СН. Анализ этого биомаркера помогает в определении тактики противоотечной терапии. Включение CA-125 в сочетании с N-концевым предшественником мозгового натрийуретического пептида (NT-proBNP) может предоставить более точную оценку риска, чем использование одного лишь NT-proBNP. Несмотря на распространенность анализа на CA-125, для повышения результативности скрининга и своевременной диагностики, интерпретация уровней этого маркера должна осуществляться врачами в комплексе с оценкой клинической картины, результатами других биохимических анализов, ультразвуковых исследований и других методов комплексной диагностики.

Annotation

Heart failure (HF) is one of the main problems of modern healthcare. Research focused on the search for new biological markers can significantly affect the improvement of early detection and the choice of more effective therapies for patients with cardiovascular diseases. The range of scientific interests of researchers has recently included the study of carbohydrate antigen 125 (CA-125). CA-125 is a high molecular weight transmembrane glycoprotein belonging to the mucin family. CA-125 levels are elevated in almost two thirds of patients with acute HF. Clinical studies emphasize the importance of CA-125 as a biomarker in the context of the diagnosis and prognosis of HF. The analysis of this biomarker helps in determining the tactics of decongestant therapy. The inclusion of CA-125 in combination with the N-terminal precursor of the brain natriuretic peptide (NT-proBNP) may provide a more accurate risk assessment than using NT-proBNP alone. Despite the prevalence of analysis for CA-125, in order to improve the effectiveness of screening and timely diagnosis, the interpretation of levels of this marker should be carried out by doctors in conjunction with an assessment of the clinical picture, the results of other biochemical analyses, ultrasound examinations and other methods of complex diagnostics.
Key words: heart failure; biomarkers; CA-125; NT-proBNP

Об авторах

Список литературы

ЛИТЕРАТУРА
Бойцов С.А. Хроническая сердечная недостаточность: эволюция этиологии, распространенности и смертности за последние 20 лет. Терапевтический архив. 2022; 94(1):5–8. DOI: 10.26442/00403660.2022.01.201317.
Алиева А.М., Теплова Н.В., Батов М.А., Воронкова К.В., Валиев Р.К., Шнахова Л.М. и др. Пентраксин-3 – перспективный биологический маркер при сердечной недостаточности: литературный обзор. Consilium Medicum. 2022; 24(1):53-9. DOI: 10.26442/20751753.2022.1.201382.
Алиева А.М., Резник Е.В., Пинчук Т.В., Аракелян Р.А., Валиев Р.К., Рахаев А.М. и др. Фактор дифференцировки роста-15 (GDF-15) как биологический маркер при сердечной недостаточности. Архивъ внутренней медицины. 2023; 13(1):14-23. DOI: 10.20514/2226-6704-2023-13-1-14-23.
Алиева А.М., Теплова Н.В., Кисляков В.А., Воронкова К.В., Шнахова Л.М., Валиев Р.К. и др. Биомаркеры в кардиологии: микроРНК и сердечная недостаточность. Терапия. 2022; 1:60-70. DOI:10.18565/therapy.2022.1.60-70.
Dochez V., Caillon H., Vaucel E., Dimet J., Winer N., Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J. Ovarian. Res. 2019; 12(1):28. DOI: 10.1186/s13048-019-0503-7.
Bottoni P., Scatena R. The role of CA 125 as tumor marker: biochemical and clinical aspects. Adv. Exp. Med. Biol. 2015; 867:229-44. DOI: 10.1007/978-94-017-7215-0_14.
Miralles C., Orea M., España P., Provencio M., Sánchez A., Cantos B. et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann. Surg. Oncol. 2003; 10(2):150-4. DOI: 10.1245/aso.2003.05.015.
Marinescu M.C., Oprea V.D., Munteanu S.N., Nechita A., Tutunaru D., Nechita L.C. et al. Carbohydrate antigen 125 (CA 125): a novel biomarker in acute heart failure. Diagnostics (Basel). 2024; 14(8):795. DOI: 10.3390/diagnostics14080795.
Núñez J., de la Espriella R., Miñana G., Santas E., Llácer P., Núñez E. et al. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. Eur. J. Heart. Fail. 2021;23(9):1445-57. DOI: 10.1002/ejhf.2295.
Bastos J.M., Scala N., Perpétuo L., Mele B.H., Vitorino R. Integrative bioinformatic analysis of prognostic biomarkers in heart failure: Insights from clinical trials. Eur. J. Clin. Invest. 2025; 55(4): e70010. DOI: 10.1111/eci.70010.
Núñez J., Miñana G., Núñez E., Chorro F.J., Bodí V., Sanchis J. Clinical utility of antigen carbohydrate 125 in heart failure. Heart Fail. Rev. 2014; 19(5):575-84. DOI: 10.1007/s10741-013-9402-y.
Llàcer P., Bayés-Genís A., Núñez J. Carbohydrate antigen 125 in heart failure. New era in the monitoring and control of treatment. Med. Clin. (Barc). 2019; 152(7):266-73. English, Spanish. DOI: 10.1016/j.medcli.2018.08.020.
Scholler N., Urban N. CA125 in ovarian cancer. Biomark. Med. 2007; 1(4):513-23. DOI: 10.2217/17520363.1.4.513.
Zeillemaker A.M., Verbrugh H.A., Hoynck van Papendrecht A.A., Leguit P. CA 125 secretion by peritoneal mesothelial cells. J. Clin. Pathol. 1994; 47:263–5. DOI: 10.1136/jcp.47.3.263.
Miñana G., Núñez J., Sanchis J., Bodí V., Núñez E., Llàcer A. CA125 and immunoinflammatory activity in acute heart failure. Int. J. Cardiol. 2010;145(3):547-8. DOI: 10.1016/j.ijcard.2010.04.081.
Feng R., Zhang Z., Fan Q. Carbohydrate antigen 125 in congestive heart failure: ready for clinical application? Front Oncol. 2023; 13:1161723. DOI: 10.3389/fonc.2023.1161723.
Eiras S., de la Espriella R., Fu X., Iglesias-Álvarez D., Basdas R., Núñez-Caamaño J.R. et al. Carbohydrate antigen 125 on epicardial fat and its association with local inflammation and fibrosis-related markers. J. Transl. Med. 2024;22(1):619. DOI: 10.1186/s12967-024-05351-z.
Nägele H., Bahlo M., Klapdor R., Schaeperkoetter D., Rödiger W. CA125 and its relation to cardiac function. Am. Heart J. 1999; 137(6):1044–9. DOI: 10.1016/S0002-8703(99)70360-1.
Gruson D., Maisin D., Pouleur A.C., Ann S.A., Rousseau M.F. CA125, galectin-3 and FGF-23 are interrelated in heart failure with reduced ejection fraction. EJIFCC. 2023; 34(2):103-9. PMID: 37455845.
Menghoum N., Badii M.C., Deltombe M., Lejeune S., Roy C., Vancraeynest D. et al. Carbohydrate antigen 125: a useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail. 2024; 11(3):1493-1505. DOI: 10.1002/ehf2.14699.
Zhang J., Li W., Xiao J., Hui J., Li Y. Prognostic significance of carbohydrate antigen 125 in stage D heart failure. BMC Cardiovasc. Disord. 2023; 23(1):108. DOI: 10.1186/s12872-023-03139-5.
Li K.H.C., Gong M., Li G., Baranchuk A., Liu T., Wong M.C.S. et al. Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis. Heart Asia. 2018; 10(2): e011044. DOI: 10.1136/heartasia-2018-011044.
D’Aloia A., Faggiano P., Aurigemma G., Bontempi L., Ruggeri G., Metra M. et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and doppler echocardiographic abnormalities, and short-term prognosis. J. Am. Col.l Cardiol. 2003; 41(10):1805-11. DOI: 10.1016/s0735-1097(03)00311-5.
Zhang Y., Jin Q., Zhao Z., Zhao Q., Yu X., Yan L. et al. Carbohydrate antigen 125 is a biomarker of the severity and prognosis of pulmonary hypertension. Front Cardiovasc. Med. 2021; 8:699904. DOI: 10.3389/fcvm.2021.699904.
Ma W., Zhang P., Hu H. Serum levels of Hcy, sST2 and CA-125 in CHF patients and their correlation with cardiac function classification. Heart Surg. Forum. 2023; 26(5): E449-E454. DOI: 10.59958/hsf.5691.
Bulska-Będkowska W., Chełmecka E., Owczarek A.J., Mizia-Stec K., Witek A., Szybalska A. et al. CA125 as a marker of heart failure in the older women: population-based analysis. J. Clin. Med. 2019; 8(5):607. DOI: 10.3390/jcm8050607.
Gruson D., Maisin D., Pouleur A.C., Ann S.A., Rousseau M.F. CA125, galectin-3 and FGF-23 are interrelated in heart failure with reduced ejection fraction. EJIFCC. 2023; 34(2):103-9. PMID: 37455845.
Gayán Ordás J., Nuñez J., Bascompte Claret R., Llacer P., Zegri-Reiriz I., de la Espriella R. et al. Usefulness of antigen carbohydrate 125 and n-terminal pro-b-type natriuretic peptide for Assessing Congestion in Chronic Heart Failure: Insights from the CARDIOREN Registry. Cardiorenal Med. 2024; 14(1):543-55. DOI: 10.1159/000541324.
Núñez J., Bayés-Genís A., Revuelta-López E., Miñana G., Santas E., Ter Maaten J.M. et al. Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. Rev. Esp. Cardiol. (Engl Ed). 2022; 75(4):316-24. DOI: 10.1016/j.rec.2021.02.002.
Kaya H., Kurt R., Beton O., Zorlu A., Yucel H., Gunes H. et al. Cancer antigen 125 is associated with length of stay in patients with acute heart failure. Tex. heart inst. J. 2017; 44(1):22-8. DOI: 10.14503/THIJ-15-5626.
Llàcer P., Gallardo M.Á., Palau P., Moreno M.C., Castillo C., Fernández C. et al. Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure. Med. Clin. (Barc). 2021; 156(12):589-94. DOI: 10.1016/j.medcli.2020.05.063.
Yoon J.Y., Yang D.H., Cho H.J., Kim N.K., Kim C.Y., Son J. et al. Serum levels of carbohydrate antigen 125 in combination with N-terminal pro-brain natriuretic peptide in patients with acute decompensated heart failure. Korean J. Intern. Med. 2019; 34(4):811-8. DOI: 10.3904/kjim.2017.313.
Ding Y., Wang Q., Yang Y., Wang L. Diagnostic value of copeptin and cancer antigen 125 in acute heart failure patients with atrial fibrillation and their correlations with short-term cardiovascular events. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018; 30(11):1024-8. DOI: 10.3760/cma.j.issn.2095-4352.2018.011.003.
Xu K., Wu M., Huang M., Zhuo X., Weng Y., Chen X. Carbohydrate antigen 125 combined with N-terminal pro-B-type natriuretic peptide in the prediction of acute heart failure following ST-elevation myocardial infarction. Medicine (Baltimore). 2022; 101(48): e32129. DOI: 10.1097/MD.0000000000032129.
Soler M., Miñana G., Santas E., Núñez E., de la Espriella R., Valero E. et al. CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation. Int. J. Cardiol. 2020; 308:54-9. DOI: 10.1016/j.ijcard.2020.03.027.
Núñez-Marín G., de la Espriella R., Santas E., Lorenzo M., Miñana G., Núñez E. et al. CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure. Eur. Heart J. Acute Cardiovasc. Care. 2021; 10(5):475-83. DOI: 10.1093/ehjacc/zuab022.
García-Blas S., Bonanad C., Llàcer P., Ventura S., Núñez J.M., Sánchez R. et al. Diuretic strategies in acute heart failure and renal dysfunction: conventional vs carbohydrate antigen 125-guided strategy. Clinical trial sesign. Rev. Esp. Cardiol. (Engl. еd). 2017; 70(12):1067-73. DOI: 10.1016/j.rec.2017.02.028.
Núñez J., Llàcer P., García-Blas S., Bonanad C., Ventura S., Núñez J.M. et al. CA125-guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction. Am. J. Med. 2020; 133(3):370-380.e4. DOI: 10.1016/j.amjmed.2019.07.041.
Amiguet M., Palau P., Domínguez E., Seller J., Pinilla J.M.G., de la Espriella R. et al. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction. Sci. Rep. 2023; 13(1):10591. DOI: 10.1038/s41598-023-37491-5.
Miñana G., de la Espriella R., Lorenzo-Hernández M., Rodriguez-Borja E., Mollar A., Palau P. et al. Changes in antigen carbohydrate 125 in patients receiving dapagliflozin following an admission for acute heart failure. Cardiorenal Med. 2025; 15(1):122-32. DOI: 10.1159/000543417.
Nan Y., Tiemuerniyazi X., Chen L., Song Y., Feng W., Xu F. Prognostic value of carbohydrate antigen 125 in patients undergoing surgical left ventricular reconstruction. Int. J. Cardiol. 2023; 371:377-83. DOI: 10.1016/j.ijcard.2022.09.077.
García-Blas S., Pernias V., González D’Gregorio J., Fernández-Cisnal A., Bonanad C., Sastre C. et al. Carbohydrate antigen 125-guided pre-TAVI medical optimization: impact on quality of life and clinical outcomes. Rev. Esp. Cardiol. (Engl. Ed). 2024; 77(9):750-8. DOI: 10.1016/j.rec.2024.01.002.
Tuersun R., Abudouwayiti A., Li Y.X., Pan Y., Aimaier S., Wen Z.Y. et al. Serum CA125: a prognostic biomarker for mortality in chronic heart failure. BMC Cardiovasc. Disord. 2025; 25(1):227. DOI: 10.1186/s12872-025-04685-w.
López-Vilella R., González-Vílchez F., Guerrero Cervera B., Donoso Trenado V., Saura Carretero Z., Martínez-Solé J. et al. Predictive factors of non-elevation of carcinoembryonic antigen 125 in acute heart failure. Life (Basel). 2025; 15(3):494. DOI: 10.3390/life15030494.
Martí-Martínez A., Núñez J., López-Escribano H., Revuelta-López E., Mollar A., Peiró M. et al. The role of antigen carbohydrate 125 in modulating soluble ST2: prognostic-related effects in acute heart failure. Biomolecules. 2025; 15(4):602. DOI: 10.3390/biom15040602.
Miró Ò., Núñez J., Trullàs J.C., Noceda J., Bibiano C., Alquézar-Arbé A. et al. Carbohydrate antigen 125 determined on arrival at the emergency department correlates with severity of decompensation and adverse outcomes in patients with acute heart failure. Intern. Emerg. Med. 2025. DOI: 10.1007/s11739-025-03932-4. Online ahead of print.
Yndigegn T., Gu T., Grufman H., Erlinge D., Mokhtari A., Ekelund U. et al. Elevated carbohydrate antigen 125 (CA125) is associated with incident heart failure and mortality in acute coronary syndrome. ESC Heart Fail. 2024; 11(6):4325-34. DOI: 10.1002/ehf2.15037.
Cordero A., Velasco I., Flores E., López-Ayala J.M., Sánchez-Munuera S., Muñoz-Villalba M.P. et al. Heart failure biomarkers and prediction of early left ventricle remodeling after acute coronary syndromes. Clin. Biochem. 2024; 131-132:110814. DOI: 10.1016/j.clinbiochem.2024.110814.
Biancucci M., Barbiero R., Pennella B., Cannatà A., Ageno W., Tangianu F. et al. Hypoalbuminaemia and heart failure: A practical review of current evidence. Eur. J. Heart Fail. 2025; 27(2):293-306. DOI: 10.1002/ejhf.3363.
El Iskandarani M., El Kurdi B., Murtaza G., Paul T.K., Refaat M.M. Prognostic role of albumin level in heart failure: A systematic review and meta-analysis. Medicine (Baltimore). 2021; 100(10): e24785. DOI: 10.1097/MD.0000000000024785.
Llàcer P., Croset F., de la Espriella R., García M., Miñana G., Campos J. et al. The impact of hypoalbuminemia on the long-term prognosis of patients with acute heart failure: The modifying role of carbohydrate antigen 125. Eur. J. Intern. Med. 2025; 133:71-7. DOI: 10.1016/j.ejim.2024.12.024.
Xinastle-Castillo L.O., Landa A. Physiological and modulatory role of thioredoxins in the cellular function. Open Med. (Wars). 2022; 17(1):2021-35. DOI: 10.1515/med-2022-0596.
Erel Ö., Erdoğan S. Thiol-disulfide homeostasis: an integrated approach with biochemical and clinical aspects. Turk. J. Med. Sci. 2020; 50(SI-2):1728-38. DOI: 10.3906/sag-2003-64.
Turinay Ertop Z.Ş., Aslan A.N., Neşelioğlu S., Durmaz T. Thiol/Disulfide Homeostasis: A new oxidative marker in heart failure patients with preserved ejection fraction. Anatol. J. Cardiol. 2024; 28(8):406-12. DOI: 10.14744/AnatolJCardiol.2024.4187.
Núñez J., Llàcer P., García-Blas S., Bonanad C., Ventura S., Núñez J.M. et al. CA125-Guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction. Am. J. Med. 2020; 133: 370–380.e4. DOI: 10.1016/j.amjmed.2019.07.041.
Núñez J., Núñez E., Bayés-Genís A., Fonarow G.C., Miñana G., Bodí V. et al. Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure. Eur. Heart J. Acute Cardiovasc. Care. 2017; 6(8):685-96. DOI: 10.1177/2048872616649757.
Ordu S., Ozhan H., Alemdar R., Aydin M., Caglar O., Yuksel H. et al. Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: Compared in heart-failure prognostication. Tex. Heart Inst. J. 2012; 39:30-5. PMID: 22412224.
Du K., Tang J. New Progress of CA125 surveillance in diagnosis and treatment of ovarian cancer. Journal of Biosciences and Medicines. 2024; 12:35-44. DOI: 10.4236/jbm.2024.125004.
Weiland F., Fritz K., Oehler M., Hoffmann P. Methods for identification of CA125 from ovarian cancer ascites by high resolution mass spectrometry. Int. J. Mol. Sci. 2012; 13(8):9942-58. DOI: 10.3390/ijms13089942.

REFERENCES
Boytsov S.A. Chronic heart failure: evolution of etiology, prevalence and mortality over the past 20 years. Terapevticheskiy Arkhiv. 2022; 15; 94(1):5-8. DOI: 10.26442/00403660.2022.01.201317. (in Russian)
Alieva A.M., Teplova N.V., Batov M.A., Voronkova K.V., Valiev R.K., Shnakhova L.M. et al. Pentraxin-3 – a promising biological marker in heart failure: literature review. Consilium Medicum. 2022; 24(1):53-9. DOI: 10.26442/20751753.2022.1.201382. (in Russian)
Alieva A.M., Reznik E.V., Pinchuk T.V., Arakelyan R.A.,
Valiev R.K., Rakhaev A.M. et al. growth differentiation factor-15 (GDF-15) is a biological marker in heart failure. Archiv vnutrenney meditsiny. 2023; 13(1):14-23. DOI: 10.20514/2226-6704-2023-13-1-14-23. (in Russian)
Alieva A.M., Teplova N.V., Kislyakov V.A., Voronkova K.V.,
Shnahova L.M., Valiev R.K. et al. Biomarkers in cardiology: microRNA and heart failure. Terapiya. 2022; 1:60-70.
DOI: 10.18565/therapy.2022.1.60-70. (in Russian)
Dochez V., Caillon H., Vaucel E., Dimet J., Winer N., Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J. Ovarian. Res. 2019; 12(1):28. DOI: 10.1186/s13048-019-0503-7.
Bottoni P., Scatena R. The role of CA 125 as tumor marker: biochemical and clinical aspects. Adv. Exp. Med. Biol. 2015; 867:229-44. DOI: 10.1007/978-94-017-7215-0_14.
Miralles C., Orea M., España P., Provencio M., Sánchez A., Cantos B. et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann. Surg. Oncol. 2003; 10(2):150-4. DOI: 10.1245/aso.2003.05.015.
Marinescu M.C., Oprea V.D., Munteanu S.N., Nechita A., Tutunaru D., Nechita L.C. et al. Carbohydrate antigen 125 (CA 125): a novel biomarker in acute heart failure. Diagnostics (Basel). 2024; 14(8):795. DOI: 10.3390/diagnostics14080795.
Núñez J., de la Espriella R., Miñana G., Santas E., Llácer P., Núñez E. et al. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. Eur. J. Heart. Fail. 2021;23(9):1445-57. DOI: 10.1002/ejhf.2295.
Bastos J.M., Scala N., Perpétuo L., Mele B.H., Vitorino R. Integrative bioinformatic analysis of prognostic biomarkers in heart failure: Insights from clinical trials. Eur. J. Clin. Invest. 2025; 55(4): e70010. DOI: 10.1111/eci.70010.
Núñez J., Miñana G., Núñez E., Chorro F.J., Bodí V., Sanchis J. Clinical utility of antigen carbohydrate 125 in heart failure. Heart Fail. Rev. 2014; 19(5):575-84. DOI: 10.1007/s10741-013-9402-y.
Llàcer P., Bayés-Genís A., Núñez J. Carbohydrate antigen 125 in heart failure. New era in the monitoring and control of treatment. Med. Clin. (Barc). 2019; 152(7):266-73. English, Spanish. DOI: 10.1016/j.medcli.2018.08.020.
Scholler N., Urban N. CA125 in ovarian cancer. Biomark. Med. 2007; 1(4):513-23. DOI: 10.2217/17520363.1.4.513.
Zeillemaker A.M., Verbrugh H.A., Hoynck van Papendrecht A.A., Leguit P. CA 125 secretion by peritoneal mesothelial cells. J. Clin. Pathol. 1994; 47:263–5. DOI: 10.1136/jcp.47.3.263.
Miñana G., Núñez J., Sanchis J., Bodí V., Núñez E., Llàcer A. CA125 and immunoinflammatory activity in acute heart failure. Int. J. Cardiol. 2010;145(3):547-8. DOI: 10.1016/j.ijcard.2010.04.081.
Feng R., Zhang Z., Fan Q. Carbohydrate antigen 125 in congestive heart failure: ready for clinical application? Front Oncol. 2023; 13:1161723. DOI: 10.3389/fonc.2023.1161723.
Eiras S., de la Espriella R., Fu X., Iglesias-Álvarez D., Basdas R., Núñez-Caamaño J.R. et al. Carbohydrate antigen 125 on epicardial fat and its association with local inflammation and fibrosis-related markers. J. Transl. Med. 2024; 22(1):619. DOI: 10.1186/s12967-024-05351-z.
Nägele H., Bahlo M., Klapdor R., Schaeperkoetter D., Rödiger W. CA125 and its relation to cardiac function. Am. Heart J. 1999; 137(6):1044-9. DOI: 10.1016/S0002-8703(99)70360-1.
Gruson D., Maisin D., Pouleur A.C., Ann S.A., Rousseau M.F. CA125, galectin-3 and FGF-23 are interrelated in heart failure with reduced ejection fraction. EJIFCC. 2023; 34(2):103-9. PMID: 37455845.
Menghoum N., Badii M.C., Deltombe M., Lejeune S., Roy C., Vancraeynest D. et al. Carbohydrate antigen 125: a useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail. 2024; 11(3):1493-1505. DOI: 10.1002/ehf2.14699.
Zhang J., Li W., Xiao J., Hui J., Li Y. Prognostic significance of carbohydrate antigen 125 in stage D heart failure. BMC Cardiovasc. Disord. 2023; 23(1):108. DOI: 10.1186/s12872-023-03139-5.
Li K.H.C., Gong M., Li G., Baranchuk A., Liu T., Wong M.C.S. et al. Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis. Heart Asia. 2018; 10(2):e011044. DOI: 10.1136/heartasia-2018-011044.
D’Aloia A., Faggiano P., Aurigemma G., Bontempi L., Ruggeri G., Metra M. et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and doppler echocardiographic abnormalities, and short-term prognosis. J. Am. Col.l Cardiol. 2003; 41(10):1805-11. DOI: 10.1016/s0735-1097(03)00311-5.
Zhang Y., Jin Q., Zhao Z., Zhao Q., Yu X., Yan L. et al. Carbohydrate antigen 125 is a biomarker of the severity and prognosis of pulmonary hypertension. Front Cardiovasc. Med. 2021; 8:699904. DOI: 10.3389/fcvm.2021.699904.
Ma W., Zhang P., Hu H. Serum levels of Hcy, sST2 and CA-125 in CHF patients and their correlation with cardiac function classification. Heart Surg. Forum. 2023; 26(5): E449-E454. DOI: 10.59958/hsf.5691.
Bulska-Będkowska W., Chełmecka E., Owczarek A.J., Mizia-Stec K., Witek A., Szybalska A. et al. CA125 as a marker of heart failure in the older women: population-based analysis. J. Clin. Med. 2019; 8(5):607. DOI: 10.3390/jcm8050607.
Gruson D., Maisin D., Pouleur A.C., Ann S.A., Rousseau M.F. CA125, galectin-3 and FGF-23 are interrelated in heart failure with reduced ejection fraction. EJIFCC. 2023; 34(2):103-9. PMID: 37455845.
Gayán Ordás J., Nuñez J., Bascompte Claret R., Llacer P., Zegri-Reiriz I., de la Espriella R. et al. Usefulness of antigen carbohydrate 125 and n-terminal pro-b-type natriuretic peptide for Assessing Congestion in Chronic Heart Failure: Insights from the CARDIOREN Registry. Cardiorenal Med. 2024; 14(1):543-55. DOI: 10.1159/000541324.
Núñez J., Bayés-Genís A., Revuelta-López E., Miñana G., Santas E., Ter Maaten J.M. et al. Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. Rev. Esp. Cardiol. (Engl. ed.). 2022; 75(4):316-24. DOI: 10.1016/j.rec.2021.02.002.
Kaya H., Kurt R., Beton O., Zorlu A., Yucel H., Gunes H. et al. Cancer antigen 125 is associated with length of stay in patients with acute heart failure. Tex. heart inst. J. 2017; 44(1):22-8. DOI: 10.14503/THIJ-15-5626.
Llàcer P., Gallardo M.Á., Palau P., Moreno M.C., Castillo C., Fernández C. et al. Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure. Med. Clin. (Barc). 2021; 156(12):589-94. DOI: 10.1016/j.medcli.2020.05.063.
Yoon J.Y., Yang D.H., Cho H.J., Kim N.K., Kim C.Y., Son J. et al. Serum levels of carbohydrate antigen 125 in combination with N-terminal pro-brain natriuretic peptide in patients with acute decompensated heart failure. Korean J. Intern. Med. 2019; 34(4):811-8. DOI: 10.3904/kjim.2017.313.
Ding Y., Wang Q., Yang Y., Wang L. Diagnostic value of copeptin and cancer antigen 125 in acute heart failure patients with atrial fibrillation and their correlations with short-term cardiovascular events. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018; 30(11):1024-8. DOI: 10.3760/cma.j.issn.2095-4352.2018.011.003.
Xu K., Wu M., Huang M., Zhuo X., Weng Y., Chen X. Carbohydrate antigen 125 combined with N-terminal pro-B-type natriuretic peptide in the prediction of acute heart failure following ST-elevation myocardial infarction. Medicine (Baltimore). 2022; 101(48): e32129. DOI: 10.1097/MD.0000000000032129.
Soler M., Miñana G., Santas E., Núñez E., de la Espriella R., Valero E. et al. CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation. Int. J. Cardiol. 2020; 308:54-9. DOI: 10.1016/j.ijcard.2020.03.027.
Núñez-Marín G., de la Espriella R., Santas E., Lorenzo M., Miñana G., Núñez E. et al. CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure. Eur. Heart J. Acute Cardiovasc. Care. 2021; 10(5):475-83. DOI: 10.1093/ehjacc/zuab022.
García-Blas S., Bonanad C., Llàcer P., Ventura S., Núñez J.M., Sánchez R. et al. Diuretic strategies in acute heart failure and renal dysfunction: conventional vs carbohydrate antigen 125-guided strategy. Clinical trial sesign. Rev. Esp. Cardiol. (Engl. ed.). 2017; 70(12):1067-73. DOI: 10.1016/j.rec.2017.02.028.
Núñez J., Llàcer P., García-Blas S., Bonanad C., Ventura S., Núñez J.M. et al. CA125-guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction. Am. J. Med. 2020; 133(3):370-380.e4. DOI: 10.1016/j.amjmed.2019.07.041.
Amiguet M., Palau P., Domínguez E., Seller J., Pinilla J.M.G., de la Espriella R. et al. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction. Sci. Rep. 2023; 13(1):10591. DOI: 10.1038/s41598-023-37491-5.
Miñana G., de la Espriella R., Lorenzo-Hernández M., Rodriguez-Borja E., Mollar A., Palau P. et al. Changes in antigen carbohydrate 125 in patients receiving dapagliflozin following an admission for acute heart failure. Cardiorenal. Med. 2025; 15(1):122-32. DOI: 10.1159/000543417.
Nan Y., Tiemuerniyazi X., Chen L., Song Y., Feng W., Xu F. Prognostic value of carbohydrate antigen 125 in patients undergoing surgical left ventricular reconstruction. Int. J. Cardiol. 2023; 371:377-83. DOI: 10.1016/j.ijcard.2022.09.077.
García-Blas S., Pernias V., González D’Gregorio J., Fernández-Cisnal A., Bonanad C., Sastre C. et al. Carbohydrate antigen 125-guided pre-TAVI medical optimization: impact on quality of life and clinical outcomes. Rev. Esp. Cardiol. (Engl. Ed). 2024; 77(9):750-8. DOI: 10.1016/j.rec.2024.01.002.
Tuersun R., Abudouwayiti A., Li Y.X., Pan Y., Aimaier S., Wen Z.Y. et al. Serum CA125: a prognostic biomarker for mortality in chronic heart failure. BMC Cardiovasc. Disord. 2025; 25(1):227. DOI: 10.1186/s12872-025-04685-w.
López-Vilella R., González-Vílchez F., Guerrero Cervera B., Donoso Trenado V., Saura Carretero Z., Martínez-Solé J. et al. Predictive factors of non-elevation of carcinoembryonic antigen 125 in acute heart failure. Life (Basel). 2025; 15(3):494. DOI: 10.3390/life15030494.
Martí-Martínez A., Núñez J., López-Escribano H., Revuelta-López E., Mollar A., Peiró M. et al. The role of antigen carbohydrate 125 in modulating soluble ST2: prognostic-related effects in acute heart failure. Biomolecules. 2025; 15(4):602. DOI: 10.3390/biom15040602.
Miró Ò., Núñez J., Trullàs J.C., Noceda J., Bibiano C., Alquézar-Arbé A. et al. Carbohydrate antigen 125 determined on arrival at the emergency department correlates with severity of decompensation and adverse outcomes in patients with acute heart failure. Intern. Emerg. Med. 2025. DOI: 10.1007/s11739-025-03932-4. Online ahead of print.
Yndigegn T., Gu T., Grufman H., Erlinge D., Mokhtari A., Ekelund U. et al. Elevated carbohydrate antigen 125 (CA125) is associated with incident heart failure and mortality in acute coronary syndrome. ESC Heart Fail. 2024; 11(6):4325-34. DOI: 10.1002/ehf2.15037.
Cordero A., Velasco I., Flores E., López-Ayala J.M., Sánchez-Munuera S., Muñoz-Villalba M.P. et al. Heart failure biomarkers and prediction of early left ventricle remodeling after acute coronary syndromes. Clin. Biochem. 2024; 131-132:110814. DOI: 10.1016/j.clinbiochem.2024.110814.
Biancucci M., Barbiero R., Pennella B., Cannatà A., Ageno W., Tangianu F. et al. Hypoalbuminaemia and heart failure: A practical review of current evidence. Eur. J. Heart Fail. 2025; 27(2):293-306. DOI: 10.1002/ejhf.3363.
El Iskandarani M., El Kurdi B., Murtaza G., Paul T.K., Refaat M.M. Prognostic role of albumin level in heart failure: A systematic review and meta-analysis. Medicine (Baltimore). 2021; 100(10): e24785. DOI: 10.1097/MD.0000000000024785.
Llàcer P., Croset F., de la Espriella R., García M., Miñana G., Campos J. et al. The impact of hypoalbuminemia on the long-term prognosis of patients with acute heart failure: The modifying role of carbohydrate antigen 125. Eur. J. Intern. Med. 2025; 133:71-7. DOI: 10.1016/j.ejim.2024.12.024.
Xinastle-Castillo L.O., Landa A. Physiological and modulatory role of thioredoxins in the cellular function. Open Med. (Wars). 2022; 17(1):2021-35. DOI: 10.1515/med-2022-0596.
Erel Ö., Erdoğan S. Thiol-disulfide homeostasis: an integrated approach with biochemical and clinical aspects. Turk. J. Med. Sci. 2020; 50(SI-2):1728-38. DOI: 10.3906/sag-2003-64.
Turinay Ertop Z.Ş., Aslan A.N., Neşelioğlu S., Durmaz T. Thiol/Disulfide Homeostasis: A new oxidative marker in heart failure patients with preserved ejection fraction. Anatol. J. Cardiol. 2024; 28(8):406-12. DOI: 10.14744/AnatolJCardiol.2024.4187.
Núñez J., Llàcer P., García-Blas S., Bonanad C., Ventura S., Núñez J.M. et al. CA125-Guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction. Am. J. Med. 2020; 133: 370-380.e4. DOI: 10.1016/j.amjmed.2019.07.041.
Núñez J., Núñez E., Bayés-Genís A., Fonarow G.C., Miñana G., Bodí V. et al. Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure. Eur. Heart J. Acute Cardiovasc. Care. 2017; 6(8):685-96. DOI: 10.1177/2048872616649757.
Ordu S., Ozhan H., Alemdar R., Aydin M., Caglar O., Yuksel H. et al. Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: Compared in heart-failure prognostication. Tex. Heart Inst. J. 2012; 39:30-5. PMID: 22412224.
Du K., Tang J. New Progress of CA125 surveillance in diagnosis and treatment of ovarian cancer. Journal of Biosciences and Medicines. 2024; 12: 35-44. DOI: 10.4236/jbm.2024.125004.
Weiland F., Fritz K., Oehler M., Hoffmann P. Methods for identification of CA125 from ovarian cancer ascites by high resolution mass spectrometry. Int. J. Mol. Sci. 2012; 13(8):9942-58. DOI: 10.3390/ijms13089942.

Ключевые слова